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See related article on page 562. Reduction ascending aortoplasty (RAA) is alive, but the real questionis whether it should be. Dr Robicsek and colleagues1 deserve a lotof credit for renewing the discussion on the appropriate treatmentof ascending aortic dilatation–aneurysm. To evaluate RAA’s inev-itably requires examining the problem of decision making. This isinfluenced by many factors used to balance the risk and benefit of
nonsurgical versus surgical treatment. The risk of the nonsurgical natural course is
predominantly determined by the development of aneurysm, as well as by morbidity
and mortality caused by dissection and rupture.2 The main actors of these events are
the wall tension, as calculated by Laplace’s law, including pressure, size, and wall
thickness, and, furthermore, wall pathology (genetic collagen disorders, chronic
dissection, sex, aging, degeneration, and arteriosclerosis), hemodynamic load
caused by aortic valve pathology, concomitant aortic valve replacement, and the
growth rate of the dilatation. The benefit of the nonsurgical natural course is that
those who would never experience the above detrimental events would experience
neither its related morbidity and mortality nor the risks of surgical intervention. The
risks of surgical intervention are well known, and the benefits are associated with the
type of intervention; they are, briefly, total eradication of diseased tissue with a tube
graft, reduction of size by RAA, and external reinforcement by wrapping. In
addition to all these parameters, life expectancy and individual experience of the
surgeon contribute to decision making. Not all of these factors are equally important
or easily quantified, but the size of the ascending aorta together with aortic wall
morphology are the most important and currently used determinants.
The size of the ascending aorta depends on, among other factors, body surface
area (BSA) and, more significantly, age.3 There is now general agreement that
intervention for ascending aortic aneurysm is indicated in adults at a diameter of
greater than 5.5 cm for degenerative aneurysms.2 For patients with Marfan disease
and familial ascending aortic aneurysms, the indication is given even for smaller
diameters of between 4.5 and 5 cm, especially if size progression is observed. For
these large diameters and the special entities, there seems to be no rationale for the
RAA because too much diseased tissue is left in place, with an uncertain risk of late
complications. A prosthetic tube graft either placed supracommissural or inclusive
of the aortic root and, if necessary, extending into the aortic arch is the procedure
of choice. The tube graft is relatively simple to sew into place, with 2 circumfer-
ential suture lines and relatively low long-term risks, including thromboembolism,
false aneurysm at the suture lines, infection, and increased wall stress in the aortic
root, possibly promoting the development of aneurysms.4 The abovementioned size
thresholds, however, are rather crude, without any adjustment for patient conditions.
Evolving knowledge on the natural course, especially in patients with Marfan
disease,5 and a growth rate of 0.07 cm per year for degenerative dilatation2 indicate
that there is still a risk for typical complications if smaller dilatations are left
5untreated. Together with refined and safer operative techniques and increased





Lsurgical experience, a more aggressive policy for interven-
tion at these lower diameters seems to make sense and is
potentially lifesaving provided the risk of operation is low.
It must be emphasized, however, that there is neither gen-
eral consensus nor evidence for this policy. Thus the deci-
sion making depends more or less on some single-center
reports, unproved hypotheses, surgical experience, and the
surgeon’s discretion.
To proceed with this policy, we first have to define the
normal size that should represent a very low risk for com-
plications. It is useful to define this limit as 2 SDs above the
normal average, which presents 95% of values for normal
individuals. Although it would be desirable to integrate the
whole diversity of size-determining factors, age and BSA
are the most practical and frequently applied.3 For the
supra-aortic ridge diameter, which closely represents that of
the ascending aorta, Roman and coworkers3 provided indi-
ces for BSA in adults at different ages to calculate the upper
normal limit, as shown in Table 1.
It is now possible to take into account the different
pathologic entities by defining a special entity factor (eg,
1.10 for Marfan disease, 1.15 for bicuspid aortic valve
requiring surgical intervention, 1.20 for concomitant aortic
valve replacement, 1.20 for degenerative dilatation with
aortic insufficiency, 1.25 for bicuspid valve not requiring
valve surgery, and 1.30 for degeneration without valve
pathology) to calculate for a given patient the smallest
acceptable measured diameter requiring no surgical inter-
vention. For example, in a patient with a bicuspid aortic
valve requiring surgical intervention, a BSA of 2.0, and age
of 50 years, the calculation for the threshold diameter is as
follows: 2.0 (BSA)  1.8 (Index)  1.15 (Entity factor) 
4.1 cm. The upper acceptable absolute threshold diameters
for this aggressive policy can be defined as 4.0 cm for
Marfan disease, 4.3 cm for bicuspid valve and for degener-
ative dilatation with concomitant valve replacement, and 5.0
cm for degeneration without surgical intervention. Similar
values were suggested by Ergin and associates,6 who de-
fined the ratio of the measured and mean calculated diam-
eters as threshold values. The major objective of these
attractive, liberalized, but aggressive approaches is to tailor
the threshold values more closely to the individual’s char-
acteristics and operative techniques. Keeping in mind that
reconstruction principally preserves physiologic properties,
TABLE 1. Indices for BSA in adults at different ages for
determining the size of the ascending aorta in normal
BSA (m2) Index (cm/m2) 1.8 2.0 2.2 2.4
40 y 1.9 1.8 1.7 1.6
40 y 1.6 1.6 1.5 1.5
BSA, Body surface area. The numbers are from Roman et al.3RAA designed to reduce the size to lower than the normal
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lower size ranges exclusively in patients with poststenotic
dilatation, which is characterized by a limited convex ex-
tension of dilatation to the right. The physiologic properties
potentially being preserved by RAA include the compliance
of the ascending aorta aortic impedance and ventricular
load,7 which is increased in patients with prosthetic tube
grafts,8 leading to higher cardiac energy costs.9 In addition,
the most pathologic areas of the dilatation on the right
lateral aspect of the wall10 can be excluded by RAA most
easily performed as a plication between 2 Teflon strips.
Tubular dilatations with aortic insufficiency and also dila-
tations caused by extracellular matrix disorders like Marfan
disease do not have a rationale for RAA even not at these
lower size thresholds.
It must be considered that many yet unknown factors
could affect the outcome of RAA, such as preoperative and
postoperative size, cause, surgical technique, experience of
the surgeon, redilatation, and reoperation. Some authors
report excellent results, but others do not, and the test of
time is not proved for RAA. Whether the scope of indication
for RAA by wrapping can be extended is rather speculative
because the favorable physiologic distensibility of the
wrapped aorta is lost, the complexity of the operation is
increased, and there is a risk of later dissection possibly
triggered by under-the-wrap aortic wall atrophy or wrap
displacement. However, it is imaginable that in elderly
patients with severe comorbidity, wrapping even without
RAA potentially provides some advantages compared with
surgical intervention necessitating extracorporeal circula-
tion. When an RAA is performed, it is of particular impor-
tance to monitor these patients by means of magnetic res-
onance imaging every year.
With all due respect, the trilogy of Robicsek’s data gener-
ation (ie, the authors’ own experiences, literature review, and
extensive survey) does not provide statistically meaningful
data. Only 14.95% of addressees responded. From a statistical
point of view, 85.05% of contacted surgeons could probably
have a different opinion, making the drawn conclusions and
statements questionable and without strength for recommen-
dation or generalization. For those surgeons who answered,
which is the minority of addressees, RAA is alive but unknown
for the rest. Even more importantly, there were no randomized
trials. Apart from single-institution experiences, we do not
know with certainty whether RAA is a useful operation, which
admonishes us to indicate RAA cautiously. But experience is
the origin of theory or hypothesis that to verify or falsify is the
essence of science. After opening the discussion on different
surgical procedures for treatment of ascending aortic dilatation
and particularly with respect to a more aggressive approach, it
is now time to proceed with the implementation of a working
group for a prospective, randomized, and monitor-controlled








LFor that, we need fruitful collaboration under the auspices of
our societies to generate evidence-based guidelines for the
treatment of ascending aortic dilatation–aneurysm to optimize
the care of our patients.
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